Lenalidomide Sandoz

Lenalidomide, the active ingredient in Lenalidomide Sandoz, is an immunomodulatory drug (IMiD) presented as an oral tablet for systemic use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant sourcing for global oncology programs.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. Myelodysplastic Syndromes: reduces transfusion dependence and modifies disease course in patients with del(5q) cytogenetic abnormality. Mantle Cell Lymphoma: induces tumor regression and prolongs remission in patients with relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: upset stomach often accompanied by vomiting. - Rash: skin redness or itching. - Low blood counts: decreased neutrophils, platelets or red cells. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil count increasing infection risk. - Severe thrombocytopenia: very low platelet count leading to bleeding. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: liver enzyme elevations or liver injury.

When prescribing Lenalidomide, clinicians should observe several safety considerations. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thromboembolic prophylaxis: assess need for anticoagulation in high‑risk patients. - Renal impairment: adjust monitoring in patients with reduced kidney function. - Infection monitoring: watch for signs of infection due to neutropenia. - Hematologic monitoring: regular CBC to detect cytopenias. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with thrombocytopenia. - Immunosuppressants: heightened infection risk.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors: may increase plasma levels. - NSAIDs: additive risk of gastrointestinal bleeding. - Vaccines (live attenuated): reduced vaccine efficacy; avoid during therapy.